SCHEDULE: TCG Crossover Funds Disclose 6.9% Stake in Perspective Therapeutics

TCG Crossover Fund II, L.P., TCG Crossover Fund III, L.P., and their affiliates, along with Chen Yu, reported a combined beneficial ownership of 6.9% in Perspective Therapeutics, Inc. following a recent underwritten offering.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover Fund III, L.P., their general partners TCG Crossover GP II, LLC and TCG Crossover GP III, LLC, and Chen Yu, have filed a Schedule 13G.
• Chen Yu, as the sole managing member of the general partners, beneficially owns 7,915,567 shares of Perspective Therapeutics, Inc. common stock.
• This represents 6.9% of the company's total outstanding common stock.
• The calculation is based on 113,914,078 shares outstanding, which includes 74,337,990 shares as of November 6, 2025, and an additional 39,576,088 shares issued in an underwritten offering that closed on February 3, 2026.
• TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC each beneficially own 3,957,784 shares, representing 3.5% of the class.
• TCG Crossover Fund III, L.P. and TCG Crossover GP III, LLC each beneficially own 3,957,783 shares, representing 3.5% of the class.
• The securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the disclosure of a significant stake by institutional investors like TCG Crossover Funds typically signals confidence in the company's prospects and often follows a successful capital raise.

Positives

• Significant institutional investment by TCG Crossover Funds, indicating confidence in Perspective Therapeutics.
• Chen Yu, a key individual, holds a substantial 6.9% stake, aligning his interests with other shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant institutional investment, particularly from crossover funds, often signals a company's transition or growth phase, attracting capital from both private and public market investors. This type of filing is common after a capital raise.

Stakeholder Impact

• Shareholders: The entry of significant institutional investors can be seen as a vote of confidence, potentially stabilizing the stock.

Key Dates

Recommendation

The filing indicates a significant institutional stake by TCG Crossover Funds and Chen Yu, which is generally a positive signal of investor confidence. However, as a Schedule 13G primarily reports beneficial ownership and not detailed financial performance or strategic updates, a seasoned investor would likely maintain a "hold" position, awaiting further fundamental information before making a more aggressive investment decision. The capital raise itself, while bringing in funds, also implies dilution, the full impact of which is not detailed here.

Keywords

Perspective Therapeutics, TCG Crossover, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Shareholder Stake, Therapeutics